Featured Research

from universities, journals, and other organizations

Allen Foundation Pledges $3.2 Million For Prostatitis Research At The University Of Washington

Date:
May 14, 1997
Source:
University of Washington
Summary:
The Paul G. Allen Foundation for Medical Research has committed $3.2 million for research at the University of Washington into the causes of and cures for prostatitis, a common but under-studied infection of the prostate gland.

The Paul G. Allen Foundation for Medical Research has committed $3.2 million for research at the University of Washington into the causes of and cures for prostatitis, a common but under-studied infection of the prostate gland.

The foundation will contribute approximately $552,000 annually for the next five years to underwrite research into prostatitis conducted by the UW School of Medicine's Department of Urology. The research is under the direction of Dr. Richard E. Berger, professor of urology. The balance of the funding will go toward laboratory renovations and equipment costs.

The UW has already completed a number of significant research projects on prostatitis, funded by more than $1 million in earlier contributions from the Microsoft co-founder and philanthropist.

UW President Richard L. McCormick expressed gratitude for the gift and cited the "remarkable support in many areas" that Paul Allen and the foundations he has created have provided at the University of Washington.

"This splendid gift continues and enhances the Allen Foundation's investment in medical research, an area of giving that has been very important to the University but one that many people did not know about," said McCormick.

"We are pleased to support the University's groundbreaking research efforts and we hope that in some significant way, our gift will help to conquer this disease," said Jody Allen Patton, executive director of the Allen Foundations.

"Past financial support from the Allen Foundation has already made the UW the leader in prostatitis research," said Berger. "We have made many exciting discoveries that will offer benefits for men with chronic prostatitis. This generous new support will enable us to significantly broaden our efforts."

Despite the prevalence of prostatitis, there has been limited research into the condition, which may be the most common urologic disease of young and middle-aged men. Research has focused on the other maladies of the prostate: benign prostatic hypertrophy (BPH or enlarged prostate) and prostate cancer. Many men with BPH have symptoms of prostatitis as well.

Estimates are that up to 50 percent of men will experience symptoms of prostatitis in their lifetimes. Symptoms can be varied and severe, including genital and bladder pain, inflammation, urinary problems, and perhaps infertility. While it is often dismissed as a minor condition, the decline in quality of life with prostatitis is similar to that experienced with congestive heart failure, according to UW research. Prostatitis is frequently difficult to diagnose, and causes are usually not clear. The various bacteria known to cause it often become resistant to antibiotics.

Research directions with the new funding will include studies of the microbiology and molecular biology of prostatic tissue, development of diagnostic tests and treatment protocols, studies of host resistance factors that may cause susceptibility to infection, epidemiologic studies, and studies to determine any relationships to BPH and prostate cancer.

The Paul G. Allen Foundation for Medical Research promotes medical research in a variety of disciplines, including biochemistry, biomedical engineering, virology, immunology, cell and molecular biology, pharmacology and genetics.


Story Source:

The above story is based on materials provided by University of Washington. Note: Materials may be edited for content and length.


Cite This Page:

University of Washington. "Allen Foundation Pledges $3.2 Million For Prostatitis Research At The University Of Washington." ScienceDaily. ScienceDaily, 14 May 1997. <www.sciencedaily.com/releases/1997/05/970514120249.htm>.
University of Washington. (1997, May 14). Allen Foundation Pledges $3.2 Million For Prostatitis Research At The University Of Washington. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1997/05/970514120249.htm
University of Washington. "Allen Foundation Pledges $3.2 Million For Prostatitis Research At The University Of Washington." ScienceDaily. www.sciencedaily.com/releases/1997/05/970514120249.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins